October 14, 2025
Kailera Raises $600 Million to Launch Global Phase III Program for Obesity Drug
Kailera; obesity drug; Phase III clinical trial; KAI-9531; GLP-1/GIP dual agonist; Series B financing; Bain Capital; weight loss therapy; clinical pipeline; biotech funding
Gilead and Arcus Report Positive Results for TIGIT Approach in Gastric Cancer Trial
Gilead; Arcus; TIGIT; Gastric Cancer; Domvanalimab; Zimberelimab
Moderna Unveils Promising mRNA-4359 Cancer Antigen Therapy Data in Melanoma Ahead of ESMO 2025
Moderna; mRNA-4359; cancer antigen therapy; melanoma; ESMO 2025; checkpoint inhibitor-resistant; PD-L1; IDO1; objective response rate; disease control rate; immunotherapy; Phase 1/2 trial; pembrolizumab
Takeda Expands De Novo Protein Research with Second AI-Driven Collaboration with Nabla Bio
Takeda; Nabla Bio; de novo protein design; AI drug discovery; Joint Atomic Model (JAM); multi-year collaboration; protein therapeutics; antibody design; biopharmaceutical innovation
Johnson & Johnson to Separate Orthopaedics Business
Johnson & Johnson; Orthopaedics; DePuy Synthes; MedTech; Separation
Geron Corporation Announces Executive Leadership Transitions and Appointments
Geron Corporation; executive leadership; appointments; departures; commercial strategy; RYTELO; Harout Semerjian; Ahmed ElNawawi; Andrew Grethlein; Jim Ziegler
FDA Delays Denali’s Hunter Syndrome Therapy Decision by Three Months
FDA delay; Denali Therapeutics; Hunter syndrome; tividenofusp alfa; MPS II; Biologics License Application (BLA); review extension; clinical pharmacology; major amendment; accelerated approval
REACtiVe-2 Phase 1 Data Show Immune Activation in Pancreatic Cancer Treatment with Mitazalimab
Mitazalimab; REACtiVe-2; Metastatic Pancreatic Cancer; Immune Activation